Apparatus Another Cancer-Independent Targeted Drug Approved! Up To 84% Efficacy! Dec 10, 2025 Dec 10, 2025 Targeted drug Selpercatinib has received accelerated approval from the FDA. It is cancer-independent and may benefit any solid tumour with a positive RET gene fusion. It is up to 84% effective in selected patients with non-small cell lung cancer!
